API | moxaverine

moxaverine Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells. ^Wikipedia

Chemistry

SMILES: CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1
InChIKey: MYCMTMIGRXJNSO-UHFFFAOYSA-N
Mol. Mass: 307.39
ALogP: 4.41 Partition coefficient
ChEMBL Molecule:
moxaverine

More Chemistry

Pharmacology

Mechanism of Action:
- Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Glaucoma (Phase 2/Phase 3)

Ischemia (Phase 2)

Macular Degeneration (Phase 2/Phase 3)

Ocular Physiological Phenomena (Phase 2)

Regional Blood Flow (Phase 2/Phase 3)

Retina (Phase 2)

Vision, Ocular (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue